Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer

NCT02240537 is registered in ClinicalTrials.gov with Benovus Bio, Inc. as lead sponsor.

NCT NCT02240537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer
Lead sponsor
Benovus Bio, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2015
Completion date
June 30, 2017
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia (aml), multiple myeloma (mm), myelodysplastic syndrome (mds), smoldering multiple myeloma (smm)